A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT00585533|
Recruitment Status : Completed
First Posted : January 3, 2008
Results First Posted : November 21, 2012
Last Update Posted : July 30, 2013
This study will evaluate Tarceva in a selected population of patients with untreated advanced non-small cell lung cancer who are anticipated to have a relatively good (indolent) prognosis based on clinical criteria. It is anticipated that selection will enrich for tumor characteristic that are likely to be benefited by EGFR inhibitor treatment (survival greater than 90 days). The goal of this strategy is to provide a less toxic, oral treatment for patients with advanced NSCLC that will not interfere with patients receiving chemotherapy at some point in the future and may prolong the time to chemotherapy related progression.
Patients will remain on study until disease progresses, a decline in performance status, if patient cannot tolerate the side effects or develops symptoms requiring conventional chemotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: Erlotinib (Tarceva)||Phase 2|
Primary Objective To determine Time to Chemotherapy Progression (ie includes time on Tarceva monotherapy and chemotherapy) in advanced NSCLC
Secondary Objectives To evaluate survival and response rate associated with Tarceva treatment To study the frequency of symptom improvement (Lung Cancer Subscale)
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer|
|Study Start Date :||June 2004|
|Primary Completion Date :||March 2012|
|Study Completion Date :||March 2012|
Drug: Erlotinib (Tarceva)
Other Name: Tarceva
- Survival Rate at 6-months Chemotherapy-progression-free (CP-free) [ Time Frame: 6 months ]Will determine if 6-month chemotherapy-progression-free (CP-free) survival rate (using RECIST) is significantly higher than the historically observed 31%. A one-sided binomial test at a 5% nominal significance was used.
- Overall Survival [ Time Frame: 24 months ]Estimated via a Kaplan-Meier curves. Survival will be counted from the first dose of Tarceva.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00585533
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84112|
|Principal Investigator:||Wallace Akerley, MD||University of Utah|